Abstract 1330: Osimertinib, an irreversible next generation EGFR tyrosine kinase inhibitor, exerts anti-tumor activity in various preclinical NSCLC models harboring G719X mutant-EGFR

Authors: Nicolas Floch, Sue Bickerton, Matthew J. Martin, Darren A. Cross, Paul D. Smith

Published: 2019-08-07

DOI: 10.1158/1538-7445.am2019-1330

Source: Full article